Dominik R. Berthold

Lausanne Branch
Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Intensification of radio-hormone therapy for prostate cancer

Intensification of radio-hormone therapy for prostate cancer

Journal: Revue medicale suisse

Published: May 18, 2026

Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.

Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 24, 2025

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2025

Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. Cancers 2024, 16, 2097.

Correction: Cloître et al. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study. Cancers 2024, 16, 2097.

Journal: Cancers

Published: July 01, 2025

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 10, 2025

Superselective Intra-Arterial Lutetium-177 Prostate-Specific Membrane Antigen Therapy for Localized Nodal Metastasis in Prostate Cancer: A Case Report.

Superselective Intra-Arterial Lutetium-177 Prostate-Specific Membrane Antigen Therapy for Localized Nodal Metastasis in Prostate Cancer: A Case Report.

Journal: Journal of vascular and interventional radiology : JVIR

Published: October 10, 2024

Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.

Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 09, 2024

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Journal: Lancet (London, England)

Published: June 03, 2024

Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.

Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.

Journal: Cancers

Published: May 14, 2024

Oncology: what's new in 2023

Oncology: what's new in 2023

Journal: Revue medicale suisse

Published: January 17, 2024

Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.

Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 23, 2023

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.

Journal: Swiss medical weekly

Published: August 20, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026